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ABSTRACT
Five single nucleotide polymorphisms (SNPs) associated
with thyroid cancer (TC) risk have been reported:
rs2910164 (5q24); rs6983267 (8q24); rs965513 and
rs1867277 (9q22); and rs944289 (14q13). Most of these
associations have not been replicated in independent
populations and the combined effects of the SNPs on risk
have not been examined. This study genotyped the five
TC SNPs in 781 patients recruited through the TCUKIN
study. Genotype data from 6122 controls were obtained
from the CORGI and Wellcome Trust Case-Control
Consortium studies. Significant associations were
detected between TC and rs965513A (p¼6.3531034),
rs1867277A (p¼5.9031024), rs944289T
(p¼6.953107), and rs6983267G (p¼0.016).
rs6983267 was most strongly associated under
a recessive model (PGG vs GT + TT¼0.004), in contrast to
the association of this SNP with other cancer types.
However, no evidence was found of an association
between rs2910164 and disease under any risk model
(p>0.7). The rs1867277 association remained significant
(p¼0.008) after accounting for genotypes at the nearby
rs965513 (p¼2.331013) and these SNPs did not tag
a single high risk haplotype. The four validated TC SNPs
accounted for a relatively large proportion (w11%) of the
sibling relative risk of TC, principally owing to the large
effect size of rs965513 (OR 1.74).
INTRODUCTION
Thyroid cancer (TC) is the most common endo-
crine malignancy and a complex disease with
a largely unknown aetiology.1 TC is characterised
by one of the strongest familial relative risks in
cancer. First degree relatives of TC patients are up
to 8.6 times more likely to develop TC than the
general population.2 Most of the genetic variation
associated with TC remains uncharacterised, and it
is likely to be explained by variants of moderate or
low penetrance.
A number of recent studies have identiﬁed single
nucleotide polymorphisms (SNPs) associated with
TC risk on chromosomes 5q24, 8q24, 9q22, and
14q13.3e6 Two of these SNPs, rs965513 (9q22) and
rs944289 (14q13), were found through a multi-
stage, genome-wide association (GWA) study in the
Icelandic population.3 Subsequent replication of
association was found in smaller sample sets from
Ohio, USA and Spain.
The other three TC SNPs were discovered
through candidate gene or SNP approaches.4e6
rs2910164 (5q24) was chosen because it lay within
pre-miR-146a, a microRNA upregulated in TC. An
association with TC was found in samples from
Poland, Finland and Ohio, and the C allele at
rs2910164 was found to decrease levels of pre- and
mature miR-146A.4 rs6983267 (8q24) is associated
with the risk of several cancers, including those of
the prostate, colon and ovary, and was assessed as
a TC SNP for this reason. It showed a borderline
signiﬁcant association with TC in the Polish
population.6 rs1867277 was studied because it lies
in the 59 UTR of FOXE1 (or Thyroid Transcription
Factor 2), a key gene involved in thyroid organo-
genesis.7 rs1867277 and rs965513 are in moderate
pairwise linkage disequilibrium (LD) in Europeans
(r2¼0.39, D’¼0.73, http://www.1000genomes.
org/). rs1867277 was strongly associated with TC
risk in Spanish and Italian cohorts.5 None of the
three candidate SNP associations has been repli-
cated in independent studies.
The aim of this study was to examine these ﬁve
TC SNPs in a relatively large UK caseecontrol
sample set, to validate or refute their associations
with TC in this population, and to estimate the
proportion of the familial risk of TC for which they
account.
PATIENTS AND METHODS
Study samples
We recruited 781 white UK patients of northern
European origin with histologically conﬁrmed
non-medullary TC through the Thyroid Cancer
Genetic investigation in the UK (TCUKIN) study.
In addition to obtaining standard clinicopatholog-
ical information from medical records and a
questionnaire completed by each patient, the
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participants donated a blood sample which was used to
isolate genomic DNA. The Southampton and South West
Hampshire Research Ethics Committee (A) approved the
TCUKIN protocol.
SNP genotyping and control genotype data
We genotyped the TCUKIN samples at the ﬁve SNPs
(rs2910164, rs6983267, rs965513, rs1867277, rs944289) using the
KAspar system. Probes used to genotype these polymorphisms
are shown in supplementary table 1. For comparison, we used
available genotype data from 5193 population controls
belonging to the National Blood Donor Service (NBS) and the
1958 Birth Cohort (BC58) and 929 cancer-free controls from our
COloRectal Gene Identiﬁcation study (CORGI). The NBS and
BC58 samples had been genotyped with Illumina 1.2M
(Hap1.2M) arrays as part of the Wellcome Trust Case Control
Consortium 2,8 and the CORGI controls had been genotyped
with Illumina Hap550 arrays (Hap550, N¼932) as part of our
ongoing studies in colorectal cancer genetics.9 Two of the ﬁve
SNPs (rs2910164 and rs1867277) were not included on the
Illumina 1.2M and Hap550 arrays, but had excellent proxy
markers that facilitated their imputation. rs2910164 is perfectly
tagged (D’¼1, r2¼1) by rs2961920, a marker present on both
SNP arrays; and rs1867277 is perfectly tagged on the Hap550s by
rs1443434 and on the Hap1.2Ms by rs1867278, rs1443434,
rs1443435, and rs12348691. These genotypes were imputed
using IMPUTE210; all markers had proper_info scores >0.8 and
imputation call rates >0.95, suggesting excellent imputation. In
order to conﬁrm this excellent tagging/imputation, 94 CORGI
controls were genotyped for the TC SNPs using KAspar,
resulting in no discordant genotypes for each SNP, whether
typed or imputed.
Quality control and statistical analysis
General genotyping quality control assessment was as previ-
ously described.9 Duplicate samples were used to check geno-
typing quality and 100% concordance was found. Samples with
multiple missing genotypes were eliminated from the analyses
(N¼14). All ﬁve SNPs passed our quality control thresholds
including call rates >95% and Hardy-Weinberg equilibrium
p values >0.05.11
Association statistics were obtained on per allele, genotypic
and haplotype bases using logistic regression models imple-
mented in PLINK, R, and SNPTEST.12 13 Haplotype analyses
were carried out with HAPLOVIEW14 and PLINK. Allelic count
association meta-analyses, using the Mantel-Haenszel method,
were carried out in STATA. We used the IMPUTE2 software10
formally to generate rs2910164 and rs1867277 genotypes in the
control population, although the fact that perfect proxies were
used rendered this task of very limited utility.10 To test for
independence between SNPs, we used conditional logistic
regression models. The proportion of the familial relative risk
explained by the polymorphisms investigated in the study was
estimated using the method reported by Houlston et al.15
RESULTS
Single SNP analyses
Three of the ﬁve SNPs examined showed a signiﬁcant associa-
tion with TC risk in the UK population (table 1). The strongest
associations, on a per allele basis, were observed for the 9q22
SNPs rs965513A (p¼6.3531034, OR¼1.99, 95% CI 1.77 to 2.21)
and rs1867277A (p¼5.9031024, OR¼1.75, 95% CI 1.57 to
1.95). The association at rs944289T on 14q13 was also
convincingly replicated (p¼6.953107, OR¼1.33, 95% CI 1.18
to 1.48). For rs6983267G, we also found a nominally signiﬁcant
Table 1 Association statistics for thyroid cancer risk and genetic variants at chromosomes 5q24, 8q24,
9q22 and 14q13
SNP, genotypes
and risk allele
Frequency (%) ORs for genotype or
per allele overall (95% CI) p ValueCases Controls
rs2910164
GG 436 (0.578) 3540 (0.584) Reference
CG 271 (0.367) 2179 (0.360) 1.032 (0.876 to 1.214) 0.728
CC 41 (0.054) 339 (0.056) 0.987 (0.682 to 1.384) 0.985
Risk allele (C) 359 (0.238) 2857 (0.236) 1.013 (0.893 to 1.148) 0.845
rs6983267
TT 164 (0.218) 1441 (0.236) Reference
GT 346 (0.461) 3012 (0.493) 1.010 (0.827 to 1.236) 0.960
GG 241 (0.321) 1662 (0.272) 1.274 (1.027 to 1.583) 0.026
Risk allele (G) 674 (0.449) 5894 (0.518) 1.140 (1.025 to 1.268) 0.016
rs965513
GG 187 (0.249) 2748 (0.449) Reference
AG 394 (0.525) 2729 (0.446) 2.121 (1.763 to 2.559) 9.0831017
AA 170 (0.226) 643 (0.105) 3.883 (3.081 to 4.893) 1.3031030
Risk allele (A) 734 (0.489) 4015 (0.328) 1.981 (1.774 to 2.212) 6.3531034
rs1867277
GG 159 (0.211) 2290 (0.376) Reference
AG 398 (0.529) 2879 (0.473) 1.991 (1.638 to 2.428) 3.9931013
AA 196 (0.260) 918 (0.151) 3.074 (2.446 to 3.864) 5.9731023
Risk allele (A) 790 (0.525) 4715 (0.387) 1.749 (1.569 to 1.950) 5.9031024
rs944289
CC 87 (0.116) 1003 (0.164) Reference
CT 332 (0.441) 2924 (0.478) 1.309 (1.019 to 1.582) 0.033
TT 334 (0.444) 2193 (0.358) 1.755 (1.365 to 2.276) 4.363106
Risk allele (T) 1000 (0.664) 7310 (0.597) 1.330 (1.188 to 1.489) 6.953107
SNP, single nucleotide polymorphism.
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association with TC risk (p¼0.016, OR¼1.14, 95% CI 1.02 to
1.27, equivalent false discovery rate¼0.020). However, the
association between TC and rs2910164 was not replicated
(Pallelic¼0.85, OR¼1.01, 95% CI 0.89 to 1.14). To test if the
strength of these associations were similar in cases with
different histological types, we carried out cases-only interaction
analyses. We found no differences between cases with papillary
and follicular histology (p>0.25 for all markers, data not
shown), suggesting that these associations were not restricted to
any particular histological type of TC.
Are there multiple risk alleles on chromosome 9q22?
The 9q22 variants associated with TC risk, rs965513 and
rs1867277, were originally reported by independent and non-
overlapping GWA and candidate gene studies.3 5 Other studies
have not considered whether these SNPs represent independent
signals of association. We performed unconditional logistic
regression analyses incorporating rs1867277 and rs965513
genotypes as variables and sex as a covariate in the model. Both
the rs965513 (p¼2.3431013, OR¼1.74) and rs1867277
(p¼0.008, OR¼1.21) association signals decreased but remained
signiﬁcant. We then reconstructed haplotypes at these two loci
and estimated the ORs associated with having each one of
three possible risk haplotypes (haplotype 2¼rs965513A-
rs1867277A, haplotype 3¼rs965513G-rs1867277A, and haplo-
type 4¼rs965513A-rs1867277G, table 2) compared with the
non-risk haplotype (haplotype 1¼rs965513G-rs1867277G). As
expected, carrying the haplotype with both risk alleles (haplo-
type 2) increased disease risk signiﬁcantly (p¼2.1931036,
OR¼2.09). Carrying haplotypes with either one risk allele at
rs965513 (haplotype 3) or at rs1867277 (haplotype 4) also
increased risk, although the association signal for the haplo-
type 3 was weaker (Phaplotype 3¼0.07, ORhaplotype 3¼1.19 and
Phaplotype 4¼0.0001, ORhaplotype 4¼1.61, table 2).
We also estimated the risk associated with ‘diplotypes’ at each
the two 9q22 loci. Table 3 shows the genotype frequencies at the
two SNPs and the ORs associated with the nine possible
diplotypes. Individuals with the four risk alleles at both loci
(w7.4% of the general population) had a 4.45-fold higher risk
than non-carriers (w31.5% of the population), with the other
diplotypes having intermediate risk levels, principally dependent
on rs965513 (table 3).
These analyses showed that the two SNPs did not simply and
efﬁciently tag a single high-risk haplotype on 9q22. However,
they did not distinguish between the existence of multiple
independent risk alleles at 9q22 and a third ‘causal’ variant
tagged in complex fashion by both rs1867277 and rs965513. To
undertake a limited examination of the latter possibility, we
searched for SNPs in high/moderate LD (r2>0.5) with both
rs1867277 and rs965513 in the most recent release of the 1000
Genomes Project (phase 1, interim release, 11 May 2011, n¼762
European samples). We identiﬁed four such SNPs (rs10124220,
rs7848973, rs6478413, and rs1443432, supplementary table 2,
supplementary ﬁgure 1). However, none of these poly-
morphisms lay at a site with evidence of functional importance
(data not shown). We found no evidence for a role of non-
synonymous variants within any of the seven nearby 9q22 genes
(supplementary ﬁgure 1).
TC is associated with variation at 8q24 under a recessive model
We found evidence that rs6983267G was associated with TC in
the UK population (table 1). Interestingly, and unlike previous
ﬁndings in other cancer types, rs6983267G was associated with
TC risk according to a recessive model (tables 1 and 4). We found
no difference in risk between non-carriers and heterozygotes
(OR¼1.01, 95% CI 0.83 to 1.24, p¼0.921, table 1), but a signiﬁ-
cantly increased risk when homozygous carriers (GG) were
compared to non-carriers (p¼0.016, OR¼1.140, table 1), to
heterozygotes (p¼0.009, OR¼1.27, table 1), and to non-carriers/
heterozygotes (p¼0.004, OR¼1.26, table 4). Wokolorczyk et al6
had previously found relatively weak evidence of association
between TC and the rs6983267 SNP in the Polish population
Table 2 Thyroid cancer risk associated with different haplotypes, defined by rs965513 and rs1867277
alleles, at chromosome 9q22
Haplotype rs965513 rs1867277
Frequency
OR p ValueCases Controls
1 G G 0.413 0.561 Reference
2 A A 0.429 0.276 2.139 (1.902 to 2.407) 2.1931035
3 A G 0.097 0.111 1.189 (0.978 to 1.485) 0.077
4 G A 0.061 0.052 1.612 (1.264 to 2.037) 0.0001
Haplotype frequencies were estimated using Haploview (http://www.haploview.org/). Only samples with full data at both loci were
used for the analyses (761 cases and 6085 controls).
Table 3 Thyroid cancer risk associated with different genotype combinations (diplotypes) at rs965513
and rs1867277
rs965513 rs1867277
Frequency (%)
OR (95% CI) p ValueCases Controls
GG GG 123 (0.162) 1917 (0.315) Reference
AG 60 (0.079) 744 (0.122) 1.257 (0.897 to 1.747) 0.174
AA 7 (0.009) 73 (0.012) 1.494 (0.568 to 3.333) 0.336
AG GG 33 (0.043) 355 (0.058) 1.449 (0.939 to 2.183) 0.071
AG 300 (0.394) 1960 (0.322) 2.385 (1.908 to 2.995) 6.6231016
AA 63 (0.083) 394 (0.065) 2.491 (1.774 to 3.473) 1.103107
AA GG 4 (0.005) 17 (0.003) 3.663 (0.883 to 11.465) 0.036
AG 42 (0.055) 174 (0.029) 3.759 (2.497 to 5.580) 4.4431010
AA 129 (0.170) 451 (0.074) 4.455 (3.379 to 5.876) 8.5031027
The risk alleles are rs965513A and rs1867277A.
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(p¼0.04, OR¼0.78, 95% CI 0.63 to 1.00). We carried out a meta-
analysis of the Polish data and our data and found enhanced
support for an association between rs6983267G and TC risk,
with no evidence of inter-study heterogeneity
(Pmeta¼6.643104, per allele ORmeta¼1.15, 95% CI 1.06 to 1.25,
Pheterogeneity¼0.841, supplementary ﬁgure 2). The meta-analysis
continued to support a recessive effect of the rs6983767G allele
on risk (OR >1.2, p<0.004, table 4) and found no difference in
risk between heterozygous and non-carriers (OR¼1.087,
p¼0.142, table 4).
rs2910164 at the pre-miR-146a locus is not associated with TC
Using an allelic model, our study found no evidence of an
association between rs2910164 and TC risk (Pallelic¼0.85, table 1).
We conﬁrmed the absence of associations between this SNP and
TC in genotypic, dominant, recessive and trend models (p>0.71
for all models, supplementary table 3). The previous report of an
association between rs2910164 and papillary TC risk found
a highly signiﬁcant association between rs2910164 heterozy-
gosity and disease (p¼73107, OR¼1.62, 95% CI 1.3 to 2.0);
unusually, both homozygote genotypes were protective.4 We
tested this model in our data and failed to replicate an associa-
tion between rs2910164 heterozygosity and TC risk (p¼0.784;
supplementary table 3). When the analyses were restricted to
the cases that had histologically veriﬁed papillary TC we also
failed to detect association between rs2910164 and TC (p>0.784
for all models, data not shown, supplementary table 3).
Combined effects of rs6983267, rs965513, rs1867277, and
rs944289 on disease risk
We carried out case-only and case-control pairwise analyses
between all four risk SNPs associated with TC and found to no
evidence for SNPeSNP interaction (details not shown). We then
estimated the combined effects of the four SNPs on risk. To
incorporate the effects of the two 9q22 markers in the combined
risk analyses, we used the estimates obtained in our diplotype
analyses (table 3). Using this information, we estimated that the
risk for those individuals who are homozygous at 8q24, 9q22 and
14q13dcomprising w1.7% of the UK populationdis 9.96-fold
higher compared with individuals who do not carry any risk
allele at these loci (w1.2% of the population, table 5). The risk
homozygous at the four SNPs (17 cases and 41 controls,
supplementary table 5) have a 17.08-fold higher chance of having
TC (95% CI 3.776 to 159.323) when compared to non-risk
homozygous (two cases and 84 controls, supplementary table 5).
Contribution of 8q24, 9q22, and 14q13 variants to the familial
risk of TC
We have shown that four variants at 8q24, 9q22, and 14q13 are
associated with a signiﬁcantly higher risk of TC in the UK
population. We then determined the proportion of the sibling
relative risk of TC that they explained (15). Using a TC sibling
relative risk of 8.6 (2), we estimated that these four risk variants
explain 10.9% of the sibling relative risk of TC. Under a conser-
vative model that assumes the existence of a single risk variant
at chromosome 9q22, these loci explain at least 6.6% of the
disease heritability (supplementary table 4).
DISCUSSION
Using a relatively large sample set in a single, homogeneous
European population, we conﬁrmed associations between TC
and SNPs on chromosomes 9q22 (rs965513 and rs1867277),
14q13 (rs944289), and 8q24 (rs6983267). However, we failed
to replicate an association between SNP rs2910164 on 5q24 and
TC risk.
The 9q22 SNPs rs965513 and rs1867277 have not previously
been genotyped in the same samples. We have found that there
is not a single TC risk haplotype on 9q22 that is perfectly
denoted by rs965513 and rs1867277. Conversely, the association
cannot be explained entirely by genotypes at only one of the
two SNPs, although logistic regression analysis incorporating
both SNPs did lead to a considerably reduced association signal
for both SNPs, particularly rs1867277. We suggest, therefore,
that rs965513 and rs1867277 tag a third variant (or variants)
that is the functional variation near FOXE1. Perhaps contrary to
the genetic data, Landa et al5 showed that rs1867277A affected
FOXE1 transcript levels through the differential recruitment of
the USF1/USF2 transcription factors and suggested that
rs1867277 was a TC-causal SNP. Fine mapping studies at this
site might beneﬁt from the use of non-European samples. For
example, the LD between rs965513 and rs1867277 is signiﬁ-
cantly weaker in populations of African (r2¼0.01, D’¼0.078) or
Asian (r2¼0.00, D’¼0.014) ancestry (data from the 1000
Genomes Project). Finally, although challenging,16 rare variants
at FOXE1 deserve further scrutiny.
Our study validated the association between TC and
rs6983267 and extended the range of cancer types associated
with this variant. Interestingly, however, we found that
rs6983267G is associated with TC risk in a recessive fashion; all
other rs6983267 cancer associations follow an allelic dosage
model. Recessive cancer predisposition SNPs have rarely been
Table 4 Evidence that the association between rs6983267 and thyroid cancer risk is best explained by
a recessive model
Test
UK only Meta analysis of UK and Polish studies
OR (95% CI) p Value OR (95% CI) p Value
GG vs (GT + TT) 1.266 (1.071 to 1.494) 0.004 1.250 (1.089 to 1.435) 7.643104
GG vs GT 1.262 (1.055 to 1.509) 0.009 1.215 (1.051 to 1.404) 0.004
GT vs TT 1.010 (0.827 to 1.236) 0.960 1.087 (0.933 to 1.266) 0.142
Note that the risk allele homozygotes (GG) have significantly higher frequency compared with other genotypes combined (GT + TT)
and with heterozygotes (GT). This is also the case for the GG versus TT test which is not shown. However, there is no evidence that
heterozygotes are over-represented in cases (GT vs TT).
Table 5 Estimates to genotype relative risk at rs6983267, 9q22, and
rs944289
Locus
Non-carriers Heterozygous Homozygous carriers
Population
frequency OR
Population
frequency OR
Population
frequency
rs6983267* 0.236 NA NA 1.274 0.272
9q22y 0.315 2.385 0.322 4.455 0.074
rs944289 0.164 1.309 0.478 1.755 0.358
Combined 0.012 3.122 0.210 9.961 0.017
*rs69833267 heterozygous do not have increased risk of thyroid cancer (see tables 1
and 4).
yORs and frequencies for the 9q22 markers were obtained from the diplotype analysis
presented in table 3. Population frequency from non-carriers, heterozygous and homozygous
carriers is shown in table 3.
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found. In part, this probably reﬂects suboptimal power in GWA
studies and our ﬁnding emphasises the role of candidate SNP
analyses across cancer types. Given that rs6983267 itself may be
functional in predisposition to colorectal and other cancers,17
one possibility is that the true, recessive functional variation in
TC is not rs6983267, but an SNP in strong LD with it.
The ﬁrst association between TC and common genetic vari-
ants was found at the pre-miR-146a locus (4), a micro-RNA that
is upregulated in thyroid tumours.18 There was no good evidence
in our study of an association between rs2910164 and TC risk
under all models tested, including the heterozygous model that
showed the disease association in the study of Jazdewski et al.4
It is notable that deviations from Hardy-Weinberg equilibrium
were present in the case genotypes of Jazdewski et al; it is not
clear whether this was the result or the cause of the heterozy-
gote association with TC risk. Other possible explanations for
the differences between Jazdewski et al’s study and our own
include chance, systematic differences between cases and
controls (whether related to ascertainment or technical issues)
and population speciﬁc effects in either study.
The four validated TC risk SNPs explain an approximately 10-
fold differential risk between those with all high risk alleles and
those with all low risk alleles. Moreover, owing to the large
effect size associated with the 9q22 SNPs, the four SNPs explain
over 10% of the total sibling relative risk of TC, despite the fact
that TC has one of the largest familial relative risks reported for
any malignancy. It is highly plausible that future studies
involving only a few thousand cases and controls could identify
additional important common risk variants for this common
disease.
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